Naomi Sullivan, MD
Rheumatology · Bellingham, WANPI 1467436493
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 297 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.
Across 297 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- E.r. Squibb & Sons, L.L.C.$661
- UCB, Inc.$526
- AstraZeneca$465
- GSK$417
- Johnson & Johnson$387
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,61199%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 61 | $1,081 |
| E.r. Squibb & Sons, L.L.C. | 37 | $661 |
| UCB, Inc. | 26 | $526 |
| AstraZeneca(2 entities) | 19 | $465 |
| GSK | 23 | $417 |
| Johnson & Johnson | 22 | $387 |
| Novartis | 23 | $334 |
| Organon | 14 | $298 |
| Pfizer | 12 | $231 |
| Genentech USA, Inc. | 12 | $216 |
| AbbVie | 11 | $192 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $115 |
| Octapharma USA, Inc. | 1 | $87 |
| ANI Pharmaceuticals, Inc. | 2 | $86 |
| Kyowa Kirin, Inc. | 3 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $57 |
| Lilly USA, LLC | 3 | $56 |
| Merck | 4 | $56 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $41 |
| Sobi, Inc | 2 | $34 |
| Radius Health, Inc. | 2 | $29 |
| Sanofi | 1 | $28 |
| Boehringer Ingelheim | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $25 |
| Antares Pharma, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $22 |
| Si-bone, Inc. | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $17 |
| Celltrion USA Inc. | 1 | $15 |
How this compares
$5,655 in reported general payments places this provider in the 80th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 111 | $1,438,191 |
| Enbrel SureclickEtanercept | 112 | $856,096 |
| EnbrelEtanercept | 61 | $506,889 |
| Orencia ClickjectAbatacept | 49 | $278,217 |
| Xeljanz XrTofacitinib Citrate | 42 | $248,707 |
| XeljanzTofacitinib Citrate | 12 | $32,380 |
| Hydroxychloroquine Sulfate | 458 | $23,781 |
| MethotrexateMethotrexate Sodium | 844 | $19,109 |
| Mycophenolate Mofetil | 24 | $6,317 |
| Prednisone | 458 | $4,197 |
| Sulfasalazine DrSulfasalazine | 85 | $3,915 |
| Sulfasalazine | 81 | $2,764 |
| Pilocarpine Hcl | 27 | $2,279 |
| Leflunomide | 43 | $1,887 |
| Azathioprine | 19 | $1,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $1,081 | $506,88961 claims |
| PfizerXeljanz | $231 | $32,38012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 157 rheumatology providers in Washington.
Other rheumatology in Bellingham
- Margaret KinsellaBellingham$4K
- Stanford PengSeattle$3.5M
- Jeff PetersonBothell$2.3M
- Philip MeaseSeattle$2.1M
- Robert EttlingerTacoma$232K
- Richard JimenezBothell$155K
- Howard KenneySpokane$132K
- Arinola DadaBellevue$69K
- Verlene GauthierCovington$63K
- Jane BucknerSeattle$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.